Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 12/20 | 0.42 |
| ▸ | CSNK1E | P49674 | 12/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 5/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2524978 | 0.96 | THRB (0.44) | CSNK1DCSNK1ECHRNB4CHRNA3THRB | |
| SCHEMBL2522571 | 0.83 | THRB (0.49) | CSNK1DCSNK1ETHRBTGFBR1KDM4E | |
| SCHEMBL2524316 | 0.83 | PTGS2 (0.45) | THRBTGFBR1KDM4EALDH1A1 | |
| SCHEMBL2522902 | 0.82 | THRB (0.48) | CSNK1DCSNK1ETHRBTGFBR1KDM4E | |
| SCHEMBL2527781 | 0.79 | THRB (0.43) | CSNK1DCSNK1ETHRBTGFBR1KDM4E | |
| SCHEMBL16708796 | 0.79 | CSNK1E (0.62) | CSNK1DCSNK1E | |
| SCHEMBL2522830 | 0.79 | THRB (0.53) | CSNK1DCSNK1ETHRBTGFBR1KDM4E | |
| SCHEMBL2521875 | 0.78 | THRB (0.43) | THRBTGFBR1KDM4EALDH1A1 | |
| SCHEMBL16709096 | 0.75 | CHRNB4 (0.36) | CSNK1DCSNK1ECHRNB4CHRNA3KDM4E | |
| SCHEMBL16699295 | 0.75 | CSNK1E (0.56) | CSNK1DCSNK1E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9598423-B2 | Substituted 4,5,6,7-tetrahydropyrazolo[1,5-A]pyrazine derivatives as casein kinase 1 D/E inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-21 | — | — | US | disclosed |
| US-20160311824-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDROPYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-10-27 | — | — | US | disclosed |
| US-20160122358-A1 | NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-05-05 | — | — | US | disclosed |
| US-9273058-B2 | Substituted pyrazolo-piperazines as casein kinase 1 δ/ε inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-03-01 | — | — | US | disclosed |
| US-20150133428-A1 | NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122358-A1 | NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS | CSNK1E, CSNK1A1, CSNK1G1 | CSNK1D 7/4885CSNK1E 1/4885CHRNB4 4502/4885 |
| US-20150133428-A1 | NOVEL SUBSTITUTED PYRAZOLO-PIPERAZINES AS CASEIN KINASE 1 D/E INHIBITORS | CSNK1E, CSNK1A1, CSNK1G1 | CSNK1D 7/4885CSNK1E 1/4885CHRNB4 4502/4885 |
| US-20160311824-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDROPYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS CASEIN KINASE 1 D/E INHIBITORS | CSNK1A1, CSNK1E, CSNK1G1 | CSNK1D 6/4885CSNK1E 2/4885CHRNB4 4413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.